Holzer Holzer & Fistel, LLC is investigating potential shareholder claims on behalf of investors who currently own Optimer Pharmaceuticals, Inc., Trius Therapeutics, Inc. or Maidenform Brands, Inc. common stock. The firm is investigating whether the boards of directors complied with their fiduciary duties in approving the buyouts of their respective companies. Investors who own stock in any of these companies that would like to discuss their legal rights are encouraged to contact Holzer Holzer & Fistel, LLC and its attorneys Michael I. Fistel, Jr., Esq. ( email@example.com) or Marshall P. Dees, Esq. ( firstname.lastname@example.org) via email or via toll-free telephone at (888) 508-6832.
Optimer Pharmaceuticals, Inc.
On July 30, 2013, it was announced that Cubist Pharmaceuticals would acquire all outstanding shares of Optimer Pharmaceuticals (NASDAQ: OPTR) for $10.75 per share, plus a Contingency Value Right that would entitle the holder to an additional $5 per share if net sales targets for its drug DIFICID are achieved. The firm’s investigation seeks to determine, among other things, whether the consideration to be paid to Optimer shareholders is fair and adequate.
Trius Therapeutics, Inc.Also on July 30, 2013, Cubist Pharmaceuticals announced that it would purchase Trius Therapeutics (NASDAQ: TSRX) common stock for $13.50 per share, with an additional Contingency Value Right of $2 per share. The firm’s investigation into this proposed transaction seeks to determine if the price per share to be paid by Cubist to TSRX shareholders is fair and adequate. Maidenform Brands, Inc. On July 24, 2013, Maidenform Brands, Inc. (NYSE: MFB) announced HanesBrands was purchasing all of its outstanding stock for $23.50 per share. The firm is investigating whether Maidenform’s board of directors complied with their fiduciary duties in approving the proposed buyout. Holzer Holzer & Fistel, LLC dedicates its practice to vigorous representation of shareholders and investors in litigation nationwide, including shareholder class action and derivative litigation. More information about the firm is available through its website, www.holzerlaw.com and upon request from the firm. Holzer Holzer & Fistel, LLC has paid for the dissemination of this promotional communication, and Michael I. Fistel, Jr. is the attorney responsible for its content.